1. Copyright © 2000 American Medical Association. All rights reserved.
From: Economic Evaluation of Use of Diphtheria, Tetanus, and Acellular Pertussis Vaccine or Diphtheria, Tetanus, and Whole-Cell Pertussis Vaccine in the United States, 1997
Arch Pediatr Adolesc Med. 2000;154(8): doi: /archpedi
Figure Legend:
Sensitivity analysis of the changes in the net present value (NPV) of acellular pertussis vaccine with changes in vaccine effectiveness compared with the NPV of whole-cell pertussis vaccine.
Date of download: 10/16/2017
Copyright © 2000 American Medical Association. All rights reserved.

2. Copyright © 2000 American Medical Association. All rights reserved.
From: Economic Evaluation of Use of Diphtheria, Tetanus, and Acellular Pertussis Vaccine or Diphtheria, Tetanus, and Whole-Cell Pertussis Vaccine in the United States, 1997
Arch Pediatr Adolesc Med. 2000;154(8): doi: /archpedi
Figure Legend:
Sensitivity analysis of the impact of varying the cost of vaccination and vaccine effectiveness (VE) on the net present value (NPV) of combined diphtheria, tetanus, and acellular pertussis (DTaP) vaccination compared with the NPV of combined diphtheria, tetanus, and whole-cell pertussis (DTwP) vaccination. Total costs indicate both direct and indirect costs.
Date of download: 10/16/2017
Copyright © 2000 American Medical Association. All rights reserved.